Black Diamond Therapeutics bets on brain-penetrant EGFR drug silevertinib, targeting C797S resistance and CNS metastases as key edge in crowded lung cancer market.

BH-501284 demonstrated high potency (median IC50 of 0.83 nM) and prolonged residence time (>54 hours) in KRAS-mutant cell lines, offering ...

First-in-human study of EPI-326 will evaluate the company's lead tissue-selective EGFR degrader in patients with NSCLC and HNSCC with potential to expand to CRC AACR 2026 presentations, including New ...

A large meta-analysis found that creatinine-based and cystatin C-based eGFR results often differ significantly, with lower cystatin C estimates linked to higher mortality and cardiovascular risks in ...

EGFR Non-Small Cell Lung Cancer Market · GlobeNewswire Inc. The report offers comprehensive insights including market size, ...

The Lung Cancer Research Foundation (LCRF) announces the first recipients of its LCRF Team Science Award on Advancing Therapies Toward Curing EGFR Mutated Lung Cancers. The project, "A novel ...

A prospective cohort study found that in patients with chronic kidney disease, large differences in their glomerular filtration rate (eGFR) based on cystatin C vs creatinine were associated with risk ...

Please provide your email address to receive an email when new articles are posted on . Newer eGFR calculations that do not consider race show a link between kidney function and dementia. Equations ...